AbbVie (ABBV) Other Operating Expenses (2012 - 2026)
AbbVie (ABBV) posted quarterly Other Operating Expenses of $5.0 billion for Q1 2026, up 16.75% year-over-year from $4.2 billion in Q1 2025, and up 2186.64% quarter-over-quarter from $217.0 million in Q4 2025.
AbbVie (ABBV) Other Operating Expenses (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Other Operating Expenses for 15 consecutive years, with $5.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 16.75% year-over-year to $5.0 billion; the TTM figure through Mar 2026 stood at $5.2 billion (up 22.22% YoY), while the FY2025 annual figure was $241.0 million, up 3342.86% from the prior year.
- Other Operating Expenses rose to $5.0 billion in Q1 2026 per ABBV's latest filing, from $217.0 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $5.0 billion in Q1 2026 and bottomed at -$229.0 million in Q3 2022.
- Historically, Other Operating Expenses has averaged $958.3 million across 5 years, with a median of $96.5 million in 2023.
- Annual changes were most pronounced in 2022 — Other Operating Expenses tumbled 145.8% — and 2025, when it jumped 3000.0%.
- AbbVie's Other Operating Expenses stood at $1.0 million in 2022, then surged by 16800.0% to $169.0 million in 2023, then tumbled by 95.86% to $7.0 million in 2024, then surged by 3000.0% to $217.0 million in 2025, then soared by 2186.64% to $5.0 billion in 2026.
- Business Quant data shows ABBV's Other Operating Expenses at $5.0 billion in Q1 2026, $217.0 million in Q4 2025, and $24.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.96 Bn |
| Dec 31, 2025 | 217.00 Mn |
| Jun 30, 2025 | 24.00 Mn |
| Mar 31, 2025 | 4.25 Bn |
| Dec 31, 2024 | 7.00 Mn |
| Jun 30, 2023 | 169.00 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | -229.00 Mn |
| Jun 30, 2022 | 172.00 Mn |
| Sep 30, 2021 | 500.00 Mn |
| Jun 30, 2021 | 68.00 Mn |
| Mar 31, 2021 | 4.40 Bn |
| Mar 31, 2020 | 1.94 Bn |
| Dec 31, 2019 | 330.00 Mn |
| Sep 30, 2019 | 1.92 Bn |
| Jun 30, 2019 | 1.91 Bn |
| Mar 31, 2019 | 1.85 Bn |
| Dec 31, 2018 | 2.32 Bn |
| Sep 30, 2018 | 1.89 Bn |